Rani Therapeutics Holdings (RANI) Receivables - Other (2020 - 2024)
Rani Therapeutics Holdings (RANI) posted Receivables - Other of $428000.0 for Q4 2024, down 75.12% on a QoQ basis from $1.7 million in Q4 2020.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Receivables - Other (2020 - 2024) Analysis & Trends
Rani Therapeutics Holdings has reported Receivables - Other for 2 years, with the latest figure at $428000.0 in Q4 2024.
- On a quarterly basis, Receivables - Other changed N/A year-over-year to $428000.0 in Q4 2024; TTM through Dec 2024 was $428000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $428000.0, changed N/A from the prior year.
- Receivables - Other was $428000.0 for Q4 2024 at Rani Therapeutics Holdings, down from $1.7 million in the prior quarter.
- The five-year high for Receivables - Other was $1.7 million in Q4 2020, with the low at $428000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - |